Duhao Net

Duhao Net helps individual entrepreneurs and enterprises find high-quality suppliers, reduce procurement costs, and make transactions easier.

Anhui Biochem Pharmaceutical Co., Ltd.: A supplier of anti-HIV and anti-HBV chiral drugs

Release time：2025-06-28 10:01:11 Source：DuHao

Contact Us Today

Tel : +86 0551-6522 8207

Email: net.fei@163.com

Address: Area B, Taihe County Industrial Park, Anhui Province, China.

Anhui Biochem Pharmaceutical Co., Ltd. (ABUP) is a leading high-tech enterprise specializing in the research, production, and marketing of anti-HIV and anti-HBV chiral drugs in China. Established in 2007 (originating from Anhui Biochem Pharmaceutical founded in 2003) through a partnership with QVT Fund, the company is headquartered in Taihe County, Fuyang City, Anhui Province. With over 400 employees and total assets exceeding RMB 510 million, ABUP operates across a 50.74-acre facility.

Core Business

ABUP focuses on the development and commercialization of chemical drugs for treating AIDS, hepatitis B (HBV), and related viral diseases. The company holds 16 drug registration certificates for anti-HIV and anti-HBV preparations and is accelerating the industrialization of new drug R&D.

Integrated "API + Formulation" Strategy

Adopting an integrated development model, ABUP possesses full industrial-chain capabilities—from active pharmaceutical ingredients (APIs) to finished formulations. Key milestones include:

  • 2018: WHO prequalification (PQ) for select APIs and formulations.

  • 2019: Successful FDA on-site inspection for API production.

  • 2023: European Pharmacopoeia Certification (CEP) for certain APIs.

These achievements underscore ABUP’s readiness for global market expansion.

Innovation & Recognition

As a national-level specialized "Little Giant" enterprise and intellectual property demonstration company, ABUP boasts:

  • National Enterprise Technology Center & Postdoctoral Research Station

  • Anhui Provincial Key Laboratory of Antiviral Drugs

  • Anhui Chiral Drug Engineering Technology Research Center

  • Anhui Academician Workstation

The company has led 3 national and 7 provincial major R&D projects, earning accolades such as:

  • Anhui Science & Technology First Prize (2015)

  • China Patent Excellence Award & Anhui Patent Gold Award

Global Vision & Future Goals

ABUP’s strategy centers on:

  1. Antiviral Drug Leadership: Expanding HIV/HBV generics and advancing innovative drug R&D.

  2. Internationalization: Accelerating WHO/FDA/EMA certifications to penetrate markets in Africa (e.g., Kenya, Cameroon), Asia (India), and South America (Brazil).

  3. Green Manufacturing: Committing to sustainable production under China’s "Green Development" policy.

Chairman’s Message

"For 20 years, we’ve pursued excellence in pharmaceuticals to combat AIDS and HBV. Our mission—'Lifesaving Medicines for All'—drives us to innovate and globalize. With WHO-PQ, FDA, and EU approvals, we’re poised to serve patients worldwide."
— Wang Zhibang, Chairman

Product Portfolio

  • HIV Treatments:

    • Lopinavir/Ritonavir Tablets

    • Efavirenz Tablets (200mg/600mg)

  • HBV Therapeutics:

    • Entecavir Dispersible Tablets

  • Other Specialty Drugs:

    • Tadalafil Tablets (Kidney/Urology)

    • Selegiline Hydrochloride (Parkinson’s)

    • Metronidazole Tablets (Anti-infective)

  • APIs & Intermediates:

    • Lamivudine, Entecavir, Ritonavir, Lopinavir, and custom chiral compounds.

R&D Strength

ABUP’s 182-member R&D team (20% of workforce) drives innovation via:

  • 23 Pipeline Drugs: Including 5 Class I new drugs and generics.

  • Four-Step Strategy: "Produce-Develop-Reserve-Renew" to ensure sustained growth.

  • 52 Patents: 37 invention patents, reinforcing IP leadership.

Sustainability & Responsibility

Guided by "Quality is Life, Safety is Priority," ABUP prioritizes:

  • Affordable Medicines: Rigorous quality control aligned with global standards.

  • Eco-Friendly Production: Minimizing environmental impact.

  • Belt & Road Initiative: Partnering to improve healthcare access in developing nations.

"Climb High, Paddle Forward—The Best is Yet to Come."
ABUP remains steadfast in its quest to become a global leader in antiviral therapeutics, merging science, compassion, and innovation to shape a healthier future.

DuHao Net